Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody

Abstract

The newly identified 2019 novel coronavirus (2019-nCoV) has caused more than 11,900 laboratory-confirmed human infections, including 259 deaths, posing a serious threat to human health. Currently, however, there is no specific antiviral treatment or vaccine. Considering the relatively high identity of receptor-binding domain (RBD) in 2019-nCoV and SARS-CoV, it is urgent to assess the cross-reactivity of anti-SARS CoV antibodies with 2019-nCoV spike protein, which could have important implications for rapid development of vaccines and therapeutic antibodies against 2019-nCoV. Here, we report for the first time that a SARS-CoV-specific human monoclonal antibody, CR3022, could bind potently with 2019-nCoV RBD (KD of 6.3 nM). The epitope of CR3022 does not overlap with the ACE2 binding site within 2019-nCoV RBD. These results suggest that CR3022 may have the potential to be developed as candidate therapeutics, alone or in combination with other neutralizing antibodies, for the prevention and treatment of 2019-nCoV infections. Interestingly, some of the most potent SARS-CoV-specific neutralizing antibodies (e.g. m396, CR3014) that target the ACE2 binding site of SARS-CoV failed to bind 2019-nCoV spike protein, implying that the difference in the RBD of SARS-CoV and 2019-nCoV has a critical impact for the cross-reactivity of neutralizing antibodies, and that it is still necessary to develop novel monoclonal antibodies that could bind specifically to 2019-nCoV RBD.

Cited by papers we hold 49

• Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming? · 2022
  Not checked
• Complexity of Viral Epitope Surfaces as Evasive Targets for Vaccines and Therapeutic Antibodies · 2022
  Not checked
• Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection · 2022
  No notice
• In silico investigation of critical binding pattern in SARS-CoV-2 spike protein with angiotensin-converting enzyme 2 · 2021
  Not checked
• The Mechanisms and Animal Models of SARS-CoV-2 Infection · 2021
  Not checked
• A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2 · 2021
  Not checked
• Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19 · 2021
  No notice
• COVID‐19 and Toll‐Like Receptor 4 (TLR4): SARS‐CoV‐2 May Bind and Activate TLR4 to Increase ACE2 Expression, Facilitating Entry and Causing Hyperinflammation · 2021
  No notice
• Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19 · 2021
  No notice
• A quantitative model used to compare within-host SARS-CoV-2, MERS-CoV, and SARS-CoV dynamics provides insights into the pathogenesis and treatment of SARS-CoV-2 · 2021
  No notice
• Pathogenesis of Multiple Organ Injury in COVID-19 and Potential Therapeutic Strategies · 2021
  No notice
• Domains and Functions of Spike Protein in SARS-Cov-2 in the Context of Vaccine Design · 2021
  No notice
• Antibodies and Vaccines Target RBD of SARS-CoV-2 · 2021
  No notice
• Different Cases of SARS-CoV-2 Infection and Its Impact on Health and Economy with Special Emphasis on Antiviral Drug Targets · 2020
  Not checked
• The SARS-CoV-2 Exerts a Distinctive Strategy for Interacting with the ACE2 Human Receptor · 2020
  No notice
• Potential Therapeutic Options for COVID-19 · 2020
  Not checked
• Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals · 2020
  No notice
• Epitope based vaccine prediction for SARS-COV-2 by deploying immuno-informatics approach · 2020
  Not checked
• The COVID-19 pandemic: a global health crisis · 2020
  No notice
• Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past · 2020
  No notice

and 29 more

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.